Randomized trial examines immune dysregulation's role in depression and psychosis, suggesting pathways for treatment.
Despite compelling epidemiological, genetic, and cellular evidence linking immune dysregulation to depression and schizophrenia (and other psychotic disorders), causality remains contested and no immune biomarker has yet demonstrated robust clinical utility. Emerging methodological approaches – from target trial emulation on observational data to functional genomics – offer a potential path toward precision immunopsychiatry and stratified immunomodulatory treatment.
No takes yet. Share an insight, caveat, or question.
Formánek et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: